Statement of Ownership, Management and Circulation required by the Act of August 12, 1970; Section 3665, Title 39, United States Code

1. Date of Filing: October 1, 1980.
2. Title of Publication: CANCER RESEARCH.
3. Frequency of Issue: Monthly.
4. Location of Known Office of Publication: 428 East Preston Street, Baltimore, Maryland 21202.
5. Location of the Headquarters or General Business Offices of Publisher: 428 East Preston Street, Baltimore, Maryland 21202.
6. Publisher: The Williams & Wilkins Company, 428 East Preston Street, Baltimore, Maryland 21202.

   Editor: Dr. Peter N. Magee, Fels Research Institute, Temple University School of Medicine, Philadelphia, Pennsylvania 19140.

   Managing Editor: Miss Margaret Foti, Fels Research Institute, Temple University School of Medicine, Philadelphia, Pennsylvania 19140.

7. Owners: (If owned by a corporation, its name and address must be stated and also immediately thereunder the names and addresses of stockholders owning or holding 1 percent or more of total amount of stock. If not owned by a corporation, the names and addresses of the individual owners must be given. If owned by a partnership or other unincorporated firm, its name and address, as well as that of each individual, must be given.) Cancer Research, Inc., 1275 York Avenue, New York, NY 10021. No stockholders.

8. Known bondholders, mortgagees and other security holders owning or holding 1 percent or more of total amount of bonds, mortgages or other securities are: None.

9. Paragraphs 7 and 8 include, in cases where the stockholder or security holder appears upon the books of the company as trustee or in any other fiduciary relation, the name of the person or corporation for whom such trustee is acting, also the statements in the two paragraphs show the affiant’s full knowledge and belief as to the circumstances and conditions under which stockholders and security holders who do not appear upon the books of the company as trustees, hold stock and securities in a capacity other than that of a bona fide owner. Names and addresses of individuals who are stockholders of a corporation which itself is a stockholder or holder of bonds, mortgages or other securities of the publishing corporation have been included in Paragraphs 7 and 8 when the interest of such individuals are equivalent to 1 percent or more of the total amount of the stock or securities of the publishing corporation.

<table>
<thead>
<tr>
<th></th>
<th>(a)</th>
<th>(b)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10. A. Total No. of copies printed (net press-run)</td>
<td>6670</td>
<td>6670</td>
</tr>
<tr>
<td>B. Paid circulation</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1. To term subscribers by mail, carrier delivery</td>
<td>5708</td>
</tr>
<tr>
<td></td>
<td>or by other means</td>
<td>5708</td>
</tr>
<tr>
<td></td>
<td>2. Sales through agents, news dealers or otherwise</td>
<td>none</td>
</tr>
<tr>
<td>C. Total paid circulation</td>
<td>5708</td>
<td></td>
</tr>
<tr>
<td>D. Free distribution (including samples), by mail, carrier delivery or by other means</td>
<td>47</td>
<td></td>
</tr>
<tr>
<td>E. Total No of copies distributed</td>
<td>5755</td>
<td></td>
</tr>
<tr>
<td>F. 1. Copies not distributed</td>
<td>915</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2. Returns from news Agents</td>
<td>none</td>
</tr>
<tr>
<td>G. Total</td>
<td>6670</td>
<td></td>
</tr>
</tbody>
</table>

* Average No. of copies for each issue during preceding months.

* Single issue nearest to filing date.

I certify that the statements made by me above are correct and complete. (Signed) Robert K. Starlt, Jr., Vice President.
The Ortho ICP 22A Flow Cytometer utilizes a high power mercury arc lamp in combination with a Kohler optical system to achieve extraordinary precision and wide versatility. The capabilities of this instrument are best evaluated from the standpoint of the results it can provide. Examine the actual fluorescence histograms presented.

The high resolution of the instrument is complemented by its dual channel fluorescence detectors, which allow correlated measurements of two different dyes. Thus, the ICP 22A can provide simultaneous measurement of per cell DNA and protein content. Because of its Kohler illumination system it can even measure the DNA content of cells in which the DNA is irregularly distributed. Given the range of specific stoichiometric dyes available, its versatility is almost unmatched. To enhance that versatility still further, the ICP 22A will soon offer electronic cell volume measurement in addition to the other parameters (available September 1980).

Therapy monitoring by flow cytometric analysis

1. DNA histograms show a multiclonal tumor with four distinct tumor cell lines. Left peak in all histograms is normal cells. During three month chemotherapy with bleomycin and DTIC, the three higher ploidy tumor lines disappeared leaving only the more resistant lowest ploidy line. This biopsy series shows the different sensitivities of tumor cell lines in the same patient.

2a. At commencement of chemotherapy, the DNA histogram shows four cell lines with different ploidy stages. Left peak is normal diploid cells.

2b. After two months the DNA histogram shows suppression of three of the tumor cell lines.

2c. One month later, the DNA histogram shows the disappearance of higher ploidy tumor cell lines and the resistance of lower ploidy tumor cell line to chemotherapy.

In order to provide customers with complete support, Ortho maintains an Applications Laboratory that is available for confirmation and consultation services. Additionally, an international network of service technicians is ready to aid customers should calibration or repairs ever be required.

The Ortho ICP 22A offers remarkable precision and versatility at an exceptionally affordable price. We invite you to contact the Research Instruments Division of Ortho to find out more about the ICP Flow Cytometer. It’s available either as a stand alone flow cytometric analyzer or as part of an Ortho System 40 or 60, with dual laser illumination.

Protocols No. 28 and 29

Two new Protocols: One step Ethidium Bromide DNA/Cell Staining Procedure and DNA analysis using D.A.P.I. are available from Ortho. Write or call for your complimentary copies. (617) 329-6100

Precision, versatility and exceptional value.

The ICP Flow Cytometer
ANNUAL REVIEW
OF PUBLIC HEALTH
Volume 1

Lester Breslow, Editor
Jonathan E. Fielding, Associate Editor
Lester B. Lave, Associate Editor

The steady expansion of significant research in the field of public health has prompted the publication of this latest addition to the growing list of Annual Reviews. Each volume in this new series will cover a limited number of specific topics, but it is the intention of its Editors to present a balanced view of continuing developments in the field of public health. Included in this volume are articles on: epidemiology and health policy; scientific bases for identification of potential carcinogens and estimation of risks; biostatistics and methods of health science data analysis; assessment of the cost and quality of medical care and public health programs; and the structure and role of state and local health departments.

411 pp. $17.00 (U. S. A.), $17.50 (elsewhere).